Summit Therapeutics Inc

SMMT has triggered a clear momentum breakout and exhibits bullish medium-term structure supported by active continuation patterns. However, price is extended above rising EMAs with extreme overbought readings, warranting patience. A deferred buy on pullbacks into the rising 9/20 EMA zone aligns with speculative strategy discipline and manages risk against the longer-term downtrend.

• ↑Ibanesimab delivered statistically significant PFS in four Phase III trials.
• ↑$690.7M cash balance and zero debt fund PDUFA readiness.
• ↓Approval uncertain without statistically significant overall survival benefit.